Kate Osamor Alert Sample


Alert Sample

View the Parallel Parliament page for Kate Osamor

Information between 28th June 2025 - 18th July 2025

Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.


Division Votes
30 Jun 2025 - Business without Debate - View Vote Context
Kate Osamor voted Aye - in line with the party majority and in line with the House
One of 287 Labour Aye votes vs 0 Labour No votes
Tally: Ayes - 315 Noes - 4
1 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context
Kate Osamor voted No - against a party majority and against the House
One of 49 Labour No votes vs 333 Labour Aye votes
Tally: Ayes - 335 Noes - 260
8 Jul 2025 - Football Governance Bill [Lords] - View Vote Context
Kate Osamor voted No - in line with the party majority and in line with the House
One of 333 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 178 Noes - 338
8 Jul 2025 - Football Governance Bill [Lords] - View Vote Context
Kate Osamor voted No - in line with the party majority and in line with the House
One of 338 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 167 Noes - 346
8 Jul 2025 - Football Governance Bill [Lords] - View Vote Context
Kate Osamor voted Aye - in line with the party majority and in line with the House
One of 331 Labour Aye votes vs 1 Labour No votes
Tally: Ayes - 415 Noes - 98
8 Jul 2025 - Football Governance Bill [Lords] - View Vote Context
Kate Osamor voted No - in line with the party majority and in line with the House
One of 336 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 86 Noes - 340
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context
Kate Osamor voted No - in line with the party majority and in line with the House
One of 331 Labour No votes vs 47 Labour Aye votes
Tally: Ayes - 149 Noes - 334
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context
Kate Osamor voted No - in line with the party majority and in line with the House
One of 377 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 103 Noes - 416
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context
Kate Osamor voted No - in line with the party majority and in line with the House
One of 356 Labour No votes vs 8 Labour Aye votes
Tally: Ayes - 35 Noes - 469
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context
Kate Osamor voted Aye - in line with the party majority and in line with the House
One of 333 Labour Aye votes vs 47 Labour No votes
Tally: Ayes - 336 Noes - 242
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context
Kate Osamor voted Aye - in line with the party majority and in line with the House
One of 330 Labour Aye votes vs 37 Labour No votes
Tally: Ayes - 335 Noes - 135
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context
Kate Osamor voted No - in line with the party majority and in line with the House
One of 364 Labour No votes vs 7 Labour Aye votes
Tally: Ayes - 105 Noes - 370
15 Jul 2025 - Welfare Spending - View Vote Context
Kate Osamor voted No - in line with the party majority and in line with the House
One of 344 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 106 Noes - 440
15 Jul 2025 - Taxes - View Vote Context
Kate Osamor voted No - in line with the party majority and in line with the House
One of 333 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 165 Noes - 342


Written Answers
Tuberculosis: Drugs
Asked by: Kate Osamor (Labour (Co-op) - Edmonton and Winchmore Hill)
Tuesday 1st July 2025

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to help improve the availability of tuberculosis medication.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

Medicine supply chains are complex, global, and highly regulated, and there are a number of reasons why supply can be disrupted, many of which are not specific to the United Kingdom and are outside of Government control, including manufacturing difficulties, access to raw materials, sudden demand spikes or distribution issues, and regulatory issues. There are approximately 14,000 licensed medicines and the overwhelming majority are in good supply. Where there are supply issues, these are managed at a national level across the UK rather than at a regional level.

NHS England has been notified of some issues with medicines used to treat tuberculosis (TB), however there is sufficient stock available from alternative suppliers to meet normal demand for most of them. The products facing current disruptions include Voractiv tablets until late June 2025, and rifampicin 150 milligram capsules until mid-August 2025, both due to manufacturing delays. Comprehensive management plans were communicated to healthcare professionals on 1 June 2025, highlighting issues with TB medicines and advising of the actions to take during this time.

NHS England is actively working with the affected suppliers to address these supply issues as quickly as possible to ensure that UK patients have access to the medications they need.

The team are working intensively to improve the availability of TB medicines, which includes co-ordinating with the British Thoracic Society to ensure centres treating active TB have access to available supplies, and directing trusts to build buffer stocks of unlicensed imports of TB medicines whilst there is a supply issue with some UK licensed products. The team are also supporting the impacted supplier and trusts to ensure that the available TB medicine supplies are equitably distributed and allocated fairly across the UK. The team is continuing to explore medium to long term solutions to the supply issues, working with those mentioned as well as the Medicines and Healthcare products Regulatory Agency and clinicians within the NHS.

Tuberculosis: Drugs
Asked by: Kate Osamor (Labour (Co-op) - Edmonton and Winchmore Hill)
Tuesday 1st July 2025

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the availability of tuberculosis medication on the provision of healthcare in London.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

Medicine supply chains are complex, global, and highly regulated, and there are a number of reasons why supply can be disrupted, many of which are not specific to the United Kingdom and are outside of Government control, including manufacturing difficulties, access to raw materials, sudden demand spikes or distribution issues, and regulatory issues. There are approximately 14,000 licensed medicines and the overwhelming majority are in good supply. Where there are supply issues, these are managed at a national level across the UK rather than at a regional level.

NHS England has been notified of some issues with medicines used to treat tuberculosis (TB), however there is sufficient stock available from alternative suppliers to meet normal demand for most of them. The products facing current disruptions include Voractiv tablets until late June 2025, and rifampicin 150 milligram capsules until mid-August 2025, both due to manufacturing delays. Comprehensive management plans were communicated to healthcare professionals on 1 June 2025, highlighting issues with TB medicines and advising of the actions to take during this time.

NHS England is actively working with the affected suppliers to address these supply issues as quickly as possible to ensure that UK patients have access to the medications they need.

The team are working intensively to improve the availability of TB medicines, which includes co-ordinating with the British Thoracic Society to ensure centres treating active TB have access to available supplies, and directing trusts to build buffer stocks of unlicensed imports of TB medicines whilst there is a supply issue with some UK licensed products. The team are also supporting the impacted supplier and trusts to ensure that the available TB medicine supplies are equitably distributed and allocated fairly across the UK. The team is continuing to explore medium to long term solutions to the supply issues, working with those mentioned as well as the Medicines and Healthcare products Regulatory Agency and clinicians within the NHS.

Immigration: Applications
Asked by: Kate Osamor (Labour (Co-op) - Edmonton and Winchmore Hill)
Tuesday 15th July 2025

Question to the Home Office:

To ask the Secretary of State for the Home Department, what assessment her Department has made of the potential impact of the absence of service standards on all applications under the (a) family and (b) private life routes on applicants accessing (i) work, (ii) healthcare and (c) education.

Answered by Seema Malhotra - Parliamentary Under-Secretary of State (Department for Education) (Equalities)

Family and private life applications based on exceptionality are not subject to a service standard, however we do update GOV.UK with our average processing times and information is available in the published transparency data around consideration times.

Immigration: Applications
Asked by: Kate Osamor (Labour (Co-op) - Edmonton and Winchmore Hill)
Tuesday 15th July 2025

Question to the Home Office:

To ask the Secretary of State for the Home Department, whether her Department has plans to introduce service standards for all applications for settlement made under the (a) family and (b) private life route.

Answered by Seema Malhotra - Parliamentary Under-Secretary of State (Department for Education) (Equalities)

Applications for Indefinite Leave to Remain based on Family or Private life will be decided within six months.

Full details of current service standards can be found here:

Settlement: customer service standards - GOV.UK




Kate Osamor mentioned

Bill Documents
Jun. 18 2025
All proceedings up to 18 June 2025 at Report Stage
Crime and Policing Bill 2024-26
Bill proceedings: Commons

Found: Caroline Dinenage Euan Stainbank Neil Duncan-Jordan Connor Naismith Adrian Ramsay Jodie Gosling Kate Osamor